Viral Vaccine Cell Culture Media Market, 2022-2035
Description
Viral Vaccine Cell Culture Media Market, 2022-2035
Over the past few years, a number of advanced vaccines targeting a myriad of disease indications have received approval from various regulatory authorities. Post the onset of COVID-19, there has been a surge in the demand for viral vaccines. In fact, it is estimated that more than 4.5 billion people, across the globe, have received at least a single dose of COVID-19 vaccine. In other words, around 60% of the global population has been vaccinated against COVID-19. However, as the global population continues to rise, the demand for such vaccines is likely to be there in the foreseen future as well. Taking into consideration the prevalent trends, the global vaccines market is anticipated to be worth around USD 100 billion in 2025. Amidst the recent initiatives in this context, several viral vaccine media developers have established various partnerships for the clinical and commercial manufacturing of viral vaccines.
Vaccine production is a highly regulated and challenging process; specifically, the production of viral components or whole viruses further adds to the complexity. Additionally, it is paramount for vaccine cultures to be devoid of any contamination and be highly effective. In order to mitigate the aforementioned challenges, pharma and biotech companies are gradually adopting viral vaccine cell culture media for the manufacturing of vaccines. As a matter of fact, the recent surge in demand for vaccines amidst the COVID-19 pandemic has served to facilitate a strong case for organizations to opt such media for the development and manufacturing of large quantities of vaccines. In fact, players engaged in this domain have shifted their focus towards serum free and animal component free media to carry out vaccine manufacturing owing to the various benefits offered by these media formulations, including low contamination rate. Given that the demand for viral vaccine is indubitably rising, the corresponding opportunity for viral vaccine cell culture media is expected to witness steady growth, over the next decade.
The “Viral Vaccine Cell Culture Media Market Distribution by [A] Type of Cell Culture (Adherent and Suspension), [B] Type of Media (Animal Component Free, Protein Free and Serum Free), [C] Scale of Operation (Clinical Operations and Commercial Operations), [D] Type of End-User (Industry Players and Non-Industry Players), and [E] Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035 ” report features an extensive study of the current market landscape and the likely future potential of the viral vaccine cell culture market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report features:
A detailed overview of the overall market landscape of players engaged in the development of viral vaccine cell culture media, along with the information on their year of establishment, company size, location of headquarters. Further, it highlights a detailed assessment of the overall market landscape of over 80 viral vaccine cell culture media, based on several relevant parameters, such as type of vaccine (protein subunit, viral vector, whole virus), type of cell culture (adherent and suspension), type of cell culture media (serum free, animal component free, protein free), purpose of media (Vero cell lines, human embryonic kidney (HEK) cell lines, Madin-Darby canine kidney (MDCK) cell lines, baby hamster kidney (BHK) cell lines, Madin-Darby bovine kidney (MDBK) cell lines, other cell lines), media formulation (liquid and powder), and application area (research use and manufacturing).
Elaborate profiles of prominent players (shortlisted based on number of products being offered) engaged in the development of viral vaccine cell culture media. Each company profile features a brief overview of the company, along with information on its year of establishment, number of employees, location of headquarters, key executives, financial details / information (if available), product portfolio, recent developments and an informed future outlook.
An analysis of the recent developments and initiatives within the viral vaccine cell culture media industry, highlighting information on several partnerships and collaborations and expansion initiatives that have taken place in this domain, during the period 2015-2021.
An in-depth analysis of more than 130 vaccine developers and 50 vaccine contract manufacturers that are likely to partner with viral vaccine cell culture media providers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other vaccine development and manufacturing related capabilities.
An in-depth product competitiveness analysis of viral vaccine cell culture media based on supplier power (in terms of expertise of the developer) and key product-related specifications (such as type of media, purpose of media, application area, type of vaccine, media formulation).
An elaborative brand positioning analysis of the leading industry players (shortlisted on the basis of year of establishment and company size), highlighting the current perceptions regarding their proprietary brands across viral vaccine cell culture media.
Insightful patent analysis presenting an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered over 3400 patents that have been filed / granted for viral vaccine cell culture media, between 2015 and 2021 (till November), highlighting key trends associated with these patents, across type of patents, publication year, issuing authorities involved, emerging focus area, patent age, CPC symbols, leading patent assignees (in terms of number of patents granted / filed), patent characteristics and geography. It also includes a detailed patent benchmarking and an insightful valuation analysis.
An informed estimate of the annual demand for viral vaccine cell culture media (in terms of volume of media required for total number of cells), based on key geographical regions.
One of the key objectives of this report was to evaluate the current opportunity and the future potential associated with the viral vaccine cell culture media market, over the coming decade. We have developed an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of cell culture (adherent and suspension) [B] type of cell culture media (animal component free, protein free and serum free), [C] scale of operation (clinical operations and commercial operations), [D] type of end-user (industry players and non-industry players), and [E] key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we have conducted interviews with various experts in this domain (academia, industry, Medical practice and other associations) in order to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views
While the focus has been on forecasting the market till 2035, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
KEY QUESTIONS ANSWERED
Who are the key players engaged in the development of viral vaccine cell culture media?
Which type of cell culture is most commonly offered by viral vaccine cell culture media developers?
What type of partnership models are commonly adopted by stakeholders engaged in this industry?
What is the relative competitiveness of different viral vaccine cell culture media?
Who are the most likely partners for vaccine cell culture media developers?
What are the key challenges currently faced by stakeholders in this industry?
What are the anticipated future trends related to viral vaccine cell culture media developers?
How is the current and future market opportunity likely to be distributed across key market segments?
CHAPTER OUTLINES
Who are the key players engaged in the development of viral vaccine cell culture media?
Which type of cell culture is most commonly offered by viral vaccine cell culture media developers?
What type of partnership models are commonly adopted by stakeholders engaged in this industry?
What is the relative competitiveness of different viral vaccine cell culture media?
Who are the most likely partners for vaccine cell culture media developers?
What are the key challenges currently faced by stakeholders in this industry?
What are the anticipated future trends related to viral vaccine cell culture media developers?
How is the current and future market opportunity likely to be distributed across key market segments?
1.2. CHAPTER OUTLINES
Chapter 2 is an executive summary of key insights captured in our research. It offers a high-level view on the current state of viral vaccine cell culture media market and its likely evolution in the mid to long term.
Chapter 3 provides a general introduction to vaccine cell culture media. It further includes a detailed discussion on the vaccine components, historical evolution and development of viral vaccines, along with information on the types of viral vaccine, cell culture and cell culture media. Furthermore, it provides a brief overview of the advantages offered by cell culture media and their key limitations.
Chapter 4 provides a detailed overview of the overall market landscape of players engaged in the development of viral vaccine cell culture media, along with the information on their year of establishment, company size, location of headquarters. Further, it highlights a detailed assessment of the overall market landscape of over 80 viral vaccine cell culture media, based on several relevant parameters, such as type of vaccine (protein subunit, viral vector, whole virus), type of cell culture (adherent and suspension), type of cell culture media (serum free, animal component free, protein free), purpose of media (Vero cell lines, HEK cell lines, Madin-Darby canine kidney (MDCK) cell lines, baby hamster kidney (BHK) cell lines, Madin-Darby bovine kidney (MDBK) cell lines, other cell lines), media formulation (liquid and powder), and application area (research use and manufacturing).
Chapter 5 features elaborate profiles of prominent players (shortlisted based on number of products being offered) engaged in the development of viral vaccine cell culture media. Each company profile features a brief overview of the company, along with information on its year of establishment, number of employees, location of headquarters, key executives, financial details / information (if available), product portfolio, recent developments and an informed future outlook.
Chapter 6 provides detailed analysis of the recent developments and initiatives within the viral vaccine cell culture media industry, highlighting information on several partnerships and collaborations and expansion initiatives that have taken place in this domain, during the period 2015-2021.
Chapter 7 features an in-depth analysis of more than 130 vaccine developers and 50 vaccine contract manufacturers that are likely to partner with viral vaccine cell culture media providers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other vaccine development and manufacturing related capabilities.
Chapter 8 features an in-depth product competitiveness analysis of viral vaccine cell culture media based on supplier power (in terms of expertise of the developer) and key product-related specifications (such as type of media, purpose of media, application area, type of vaccine, media formulation).
Chapter 9 provides an elaborative brand positioning analysis of the leading industry players (shortlisted on the basis of year of establishment and company size), highlighting the current perceptions regarding their proprietary brands across viral vaccine cell culture media.
Chapter 10 provides an in-depth patent analysis presenting an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered over 2800 patents that have been filed / granted for viral vaccine cell culture media, between 2015 and 2021 (till November), highlighting key trends associated with these patents, across type of patents, publication year, issuing authorities involved, emerging focus area, patent age, CPC symbols, leading patent assignees (in terms of number of patents granted / filed), patent characteristics and geography. It also includes a detailed patent benchmarking and an insightful valuation analysis.
Chapter 11 provides an informed estimate of the annual demand for viral vaccine cell culture media (in terms of volume of media required for total number of cells), based on key geographical regions.
Chapter 12 features a detailed market forecast analysis, highlighting the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of cell culture (adherent and suspension) [B] type of cell culture media (animal component free, protein free and serum free), [C] scale of operation (clinical operations and commercial operations), [D] type of end-user (industry players and non-industry players), and [E] key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
Chapter 13 is a summary of the entire report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
Chapter 14 is a collection of interview transcripts of the discussion(s) that were held key stakeholders in the industry.
Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 16 is an appendix, which contains a list of companies and organizations mentioned in this report.
LIST OF COMPANIES AND ORGANIZATIONS
The following companies / institutes / government bodies and organizations have been mentioned in this report.
1. 2BScientific
2. Adimmune
3. Aduro Biotech
4. Advagene Biopharma
5. Advanced Bioprocessing Business (A subsidiary of Thermo Fisher Scientific)
6. Advanced BioScience Laboratories
7. Advent
8. AJ Biologics
9. Albany Molecular Research
10. Alopexx Vaccine
11. Altimmune
12. Amphera
13. Anhui Zhifei Longcom Biologic Pharmacy
14. Applied Biosystems
15. Argos Therapeutics
16. Astellas Pharma
17. Asterias Biotherapeutics
18. ATZ labs
19. Auro Vaccines
20. Aurora Biopharma
21. AVAX Technologies
22. Avid Bioservices
23. AVIR Green Hills Biotechnology
24. Batavia Biosciences
25. Bavarian Nordic
26. BD Biosciences
27. Beijing Minhai Biotechnology
28. Beijing Zhifei Lvzhu Biopharmaceutical
29. Bharat Biotech
30. Bielefeld University
31. Bio Farma
32. BioCell
33. BioConnection
34. Biofabri
35. Biological E
36. Biological Industries
37. BioMARC
38. BioReliance
39. BlueWillow Biologics
40. Boehringer Ingelheim
41. Boryung Pharmaceutical
42. BravoVax
43. Bryllan
44. CanSino Biologics
45. Capricorn Scientific
46. Catalent Biologics
47. Cellca (Acquired by Sartorius)
48. CellGenix
49. CEVEC Pharmaceuticals
50. Charles River Laboratories
51. Chengdu Zenmindes Biotechnology
52. CiMaas
53. CJ HealthCare
54. Cobra Biologics
55. Codagenix
56. Commonwealth Serum Laboratories (CSL)
57. Creative Biolabs
58. Curevo Vaccine
59. Cytiva
60. CyTuVax
61. Daiichi Sankyo
62. DanDrit Biotech
63. DCPrime
64. Dendreon
65. Elios Therapeutics
66. Emergent BioSolutions
67. Fisher Scientific (Acquired by Thermo Fisher Scientific)
68. FluGen
69. FUJIFILM Wako Pure Chemicals
70. GC Pharma
71. GeneOne Life Science
72. GlaxoSmithKline
73. Gradalis
74. HALIX
75. Heat Biologics
76. Hilleman Laboratories
77. Hookipa Biotech
78. Icahn School of Medicine at Mount Sinai
79. IDT Biologika
80. ILiAD Biotechnologies
81. Immunicum
82. ImmunoCellular Therapeutics
83. Immutep
84. Indian Immunologicals
85. Inovio Pharmaceuticals
86. Institut National de la Santé et de la Recherche Médicale (INSERM)
87. Insud Pharma
88. Intermountain Life Sciences
89. Intervet
90. InVitria
91. Invitrogen
92. Irvine Scientific Sales (Acquired by FUJIFILM)
93. IS JAPAN (Acquired by FUJIFILM)
94. Janssen Pharmaceuticals
95. Jianshun Biosciences
96. JN International Medical
97. JW CreaGene
98. Kansas State University
99. KBI Biopharma
100. Kiromic
101. Leland Stanford Junior University
102. LG Chem
103. LimmaTech Biologics
104. Lonza
105. Luina Bio
106. Massachusetts Institute of Technology
107. MassBiologics
108. Medicago
109. Medigen Vaccine Biologics
110. Medigene
111. Meissa Vaccines
112. Merck
113. Meridian Life Science
114. MilliporeSigma
115. MinervaX
116. Moderna
117. MolecuVax
118. Northwest Biotherapeutics
119. Nova Immunotherapeutics
120. Novartis
121. Novasep
122. Novavax
123. NPO Petrovax Pharm
124. Ology Bioservices
125. Oncobiomed
126. OPM Biosciences
127. Osivax
128. Oxford Biomedica
129. Pall Corporation
130. Panacea Biotec
131. Patheon Viral Vector Services
132. PDC*line Pharma
133. Pfizer
134. Premas Biotech
135. Prestige BioPharma
136. ProBioGen
137. Regeneus
138. Research Institute at Nationwide Children's Hospital
139. Sanaria
140. Sanofi Pasteur
141. Saronic Biotechnology
142. Sartorius
143. Scandinavian Biopharma
144. Seqirus
145. Serum Institute of India
146. Shanghai Bovax Biotechnology
147. Shenzhen Hornetcorn Biotechnology
148. Shenzhen Kangtai Biological Products
149. Sigma-Aldrich
150. SK Bioscience
151. SOTIO
152. Symbiosis Pharmaceutical Services
153. Takeda
154. TapImmune
155. Tella
156. Tessa Therapeutics
157. TeutoCell
158. Themis Bioscience
159. Thermo Electron
160. Thermo Fisher Scientific
161. Thousand Oaks Biopharmaceuticals
162. TNCbio
163. Unity Lab Services
164. University of California
165. University of Pennsylvania
166. University of Texas
167. USHEALTH
168. Vaccinogen
169. Vaccitech
170. Valneva
171. Vaxart
172. Vaxine
173. Vibalogics
174. Waisman Biomanufacturing
175. WuXi Biologics
176. Xell
177. XEME Biopharma
Please note that the publisher limits purchases by consulting clients to either Consulting Company Team License or Global Site License for Entire Company. Any other selections will not be fulfilled by this publisher.
Over the past few years, a number of advanced vaccines targeting a myriad of disease indications have received approval from various regulatory authorities. Post the onset of COVID-19, there has been a surge in the demand for viral vaccines. In fact, it is estimated that more than 4.5 billion people, across the globe, have received at least a single dose of COVID-19 vaccine. In other words, around 60% of the global population has been vaccinated against COVID-19. However, as the global population continues to rise, the demand for such vaccines is likely to be there in the foreseen future as well. Taking into consideration the prevalent trends, the global vaccines market is anticipated to be worth around USD 100 billion in 2025. Amidst the recent initiatives in this context, several viral vaccine media developers have established various partnerships for the clinical and commercial manufacturing of viral vaccines.
Vaccine production is a highly regulated and challenging process; specifically, the production of viral components or whole viruses further adds to the complexity. Additionally, it is paramount for vaccine cultures to be devoid of any contamination and be highly effective. In order to mitigate the aforementioned challenges, pharma and biotech companies are gradually adopting viral vaccine cell culture media for the manufacturing of vaccines. As a matter of fact, the recent surge in demand for vaccines amidst the COVID-19 pandemic has served to facilitate a strong case for organizations to opt such media for the development and manufacturing of large quantities of vaccines. In fact, players engaged in this domain have shifted their focus towards serum free and animal component free media to carry out vaccine manufacturing owing to the various benefits offered by these media formulations, including low contamination rate. Given that the demand for viral vaccine is indubitably rising, the corresponding opportunity for viral vaccine cell culture media is expected to witness steady growth, over the next decade.
The “Viral Vaccine Cell Culture Media Market Distribution by [A] Type of Cell Culture (Adherent and Suspension), [B] Type of Media (Animal Component Free, Protein Free and Serum Free), [C] Scale of Operation (Clinical Operations and Commercial Operations), [D] Type of End-User (Industry Players and Non-Industry Players), and [E] Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035 ” report features an extensive study of the current market landscape and the likely future potential of the viral vaccine cell culture market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report features:
A detailed overview of the overall market landscape of players engaged in the development of viral vaccine cell culture media, along with the information on their year of establishment, company size, location of headquarters. Further, it highlights a detailed assessment of the overall market landscape of over 80 viral vaccine cell culture media, based on several relevant parameters, such as type of vaccine (protein subunit, viral vector, whole virus), type of cell culture (adherent and suspension), type of cell culture media (serum free, animal component free, protein free), purpose of media (Vero cell lines, human embryonic kidney (HEK) cell lines, Madin-Darby canine kidney (MDCK) cell lines, baby hamster kidney (BHK) cell lines, Madin-Darby bovine kidney (MDBK) cell lines, other cell lines), media formulation (liquid and powder), and application area (research use and manufacturing).
Elaborate profiles of prominent players (shortlisted based on number of products being offered) engaged in the development of viral vaccine cell culture media. Each company profile features a brief overview of the company, along with information on its year of establishment, number of employees, location of headquarters, key executives, financial details / information (if available), product portfolio, recent developments and an informed future outlook.
An analysis of the recent developments and initiatives within the viral vaccine cell culture media industry, highlighting information on several partnerships and collaborations and expansion initiatives that have taken place in this domain, during the period 2015-2021.
An in-depth analysis of more than 130 vaccine developers and 50 vaccine contract manufacturers that are likely to partner with viral vaccine cell culture media providers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other vaccine development and manufacturing related capabilities.
An in-depth product competitiveness analysis of viral vaccine cell culture media based on supplier power (in terms of expertise of the developer) and key product-related specifications (such as type of media, purpose of media, application area, type of vaccine, media formulation).
An elaborative brand positioning analysis of the leading industry players (shortlisted on the basis of year of establishment and company size), highlighting the current perceptions regarding their proprietary brands across viral vaccine cell culture media.
Insightful patent analysis presenting an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered over 3400 patents that have been filed / granted for viral vaccine cell culture media, between 2015 and 2021 (till November), highlighting key trends associated with these patents, across type of patents, publication year, issuing authorities involved, emerging focus area, patent age, CPC symbols, leading patent assignees (in terms of number of patents granted / filed), patent characteristics and geography. It also includes a detailed patent benchmarking and an insightful valuation analysis.
An informed estimate of the annual demand for viral vaccine cell culture media (in terms of volume of media required for total number of cells), based on key geographical regions.
One of the key objectives of this report was to evaluate the current opportunity and the future potential associated with the viral vaccine cell culture media market, over the coming decade. We have developed an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of cell culture (adherent and suspension) [B] type of cell culture media (animal component free, protein free and serum free), [C] scale of operation (clinical operations and commercial operations), [D] type of end-user (industry players and non-industry players), and [E] key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we have conducted interviews with various experts in this domain (academia, industry, Medical practice and other associations) in order to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views
While the focus has been on forecasting the market till 2035, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
KEY QUESTIONS ANSWERED
Who are the key players engaged in the development of viral vaccine cell culture media?
Which type of cell culture is most commonly offered by viral vaccine cell culture media developers?
What type of partnership models are commonly adopted by stakeholders engaged in this industry?
What is the relative competitiveness of different viral vaccine cell culture media?
Who are the most likely partners for vaccine cell culture media developers?
What are the key challenges currently faced by stakeholders in this industry?
What are the anticipated future trends related to viral vaccine cell culture media developers?
How is the current and future market opportunity likely to be distributed across key market segments?
CHAPTER OUTLINES
Who are the key players engaged in the development of viral vaccine cell culture media?
Which type of cell culture is most commonly offered by viral vaccine cell culture media developers?
What type of partnership models are commonly adopted by stakeholders engaged in this industry?
What is the relative competitiveness of different viral vaccine cell culture media?
Who are the most likely partners for vaccine cell culture media developers?
What are the key challenges currently faced by stakeholders in this industry?
What are the anticipated future trends related to viral vaccine cell culture media developers?
How is the current and future market opportunity likely to be distributed across key market segments?
1.2. CHAPTER OUTLINES
Chapter 2 is an executive summary of key insights captured in our research. It offers a high-level view on the current state of viral vaccine cell culture media market and its likely evolution in the mid to long term.
Chapter 3 provides a general introduction to vaccine cell culture media. It further includes a detailed discussion on the vaccine components, historical evolution and development of viral vaccines, along with information on the types of viral vaccine, cell culture and cell culture media. Furthermore, it provides a brief overview of the advantages offered by cell culture media and their key limitations.
Chapter 4 provides a detailed overview of the overall market landscape of players engaged in the development of viral vaccine cell culture media, along with the information on their year of establishment, company size, location of headquarters. Further, it highlights a detailed assessment of the overall market landscape of over 80 viral vaccine cell culture media, based on several relevant parameters, such as type of vaccine (protein subunit, viral vector, whole virus), type of cell culture (adherent and suspension), type of cell culture media (serum free, animal component free, protein free), purpose of media (Vero cell lines, HEK cell lines, Madin-Darby canine kidney (MDCK) cell lines, baby hamster kidney (BHK) cell lines, Madin-Darby bovine kidney (MDBK) cell lines, other cell lines), media formulation (liquid and powder), and application area (research use and manufacturing).
Chapter 5 features elaborate profiles of prominent players (shortlisted based on number of products being offered) engaged in the development of viral vaccine cell culture media. Each company profile features a brief overview of the company, along with information on its year of establishment, number of employees, location of headquarters, key executives, financial details / information (if available), product portfolio, recent developments and an informed future outlook.
Chapter 6 provides detailed analysis of the recent developments and initiatives within the viral vaccine cell culture media industry, highlighting information on several partnerships and collaborations and expansion initiatives that have taken place in this domain, during the period 2015-2021.
Chapter 7 features an in-depth analysis of more than 130 vaccine developers and 50 vaccine contract manufacturers that are likely to partner with viral vaccine cell culture media providers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other vaccine development and manufacturing related capabilities.
Chapter 8 features an in-depth product competitiveness analysis of viral vaccine cell culture media based on supplier power (in terms of expertise of the developer) and key product-related specifications (such as type of media, purpose of media, application area, type of vaccine, media formulation).
Chapter 9 provides an elaborative brand positioning analysis of the leading industry players (shortlisted on the basis of year of establishment and company size), highlighting the current perceptions regarding their proprietary brands across viral vaccine cell culture media.
Chapter 10 provides an in-depth patent analysis presenting an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered over 2800 patents that have been filed / granted for viral vaccine cell culture media, between 2015 and 2021 (till November), highlighting key trends associated with these patents, across type of patents, publication year, issuing authorities involved, emerging focus area, patent age, CPC symbols, leading patent assignees (in terms of number of patents granted / filed), patent characteristics and geography. It also includes a detailed patent benchmarking and an insightful valuation analysis.
Chapter 11 provides an informed estimate of the annual demand for viral vaccine cell culture media (in terms of volume of media required for total number of cells), based on key geographical regions.
Chapter 12 features a detailed market forecast analysis, highlighting the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of cell culture (adherent and suspension) [B] type of cell culture media (animal component free, protein free and serum free), [C] scale of operation (clinical operations and commercial operations), [D] type of end-user (industry players and non-industry players), and [E] key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
Chapter 13 is a summary of the entire report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
Chapter 14 is a collection of interview transcripts of the discussion(s) that were held key stakeholders in the industry.
Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 16 is an appendix, which contains a list of companies and organizations mentioned in this report.
LIST OF COMPANIES AND ORGANIZATIONS
The following companies / institutes / government bodies and organizations have been mentioned in this report.
1. 2BScientific
2. Adimmune
3. Aduro Biotech
4. Advagene Biopharma
5. Advanced Bioprocessing Business (A subsidiary of Thermo Fisher Scientific)
6. Advanced BioScience Laboratories
7. Advent
8. AJ Biologics
9. Albany Molecular Research
10. Alopexx Vaccine
11. Altimmune
12. Amphera
13. Anhui Zhifei Longcom Biologic Pharmacy
14. Applied Biosystems
15. Argos Therapeutics
16. Astellas Pharma
17. Asterias Biotherapeutics
18. ATZ labs
19. Auro Vaccines
20. Aurora Biopharma
21. AVAX Technologies
22. Avid Bioservices
23. AVIR Green Hills Biotechnology
24. Batavia Biosciences
25. Bavarian Nordic
26. BD Biosciences
27. Beijing Minhai Biotechnology
28. Beijing Zhifei Lvzhu Biopharmaceutical
29. Bharat Biotech
30. Bielefeld University
31. Bio Farma
32. BioCell
33. BioConnection
34. Biofabri
35. Biological E
36. Biological Industries
37. BioMARC
38. BioReliance
39. BlueWillow Biologics
40. Boehringer Ingelheim
41. Boryung Pharmaceutical
42. BravoVax
43. Bryllan
44. CanSino Biologics
45. Capricorn Scientific
46. Catalent Biologics
47. Cellca (Acquired by Sartorius)
48. CellGenix
49. CEVEC Pharmaceuticals
50. Charles River Laboratories
51. Chengdu Zenmindes Biotechnology
52. CiMaas
53. CJ HealthCare
54. Cobra Biologics
55. Codagenix
56. Commonwealth Serum Laboratories (CSL)
57. Creative Biolabs
58. Curevo Vaccine
59. Cytiva
60. CyTuVax
61. Daiichi Sankyo
62. DanDrit Biotech
63. DCPrime
64. Dendreon
65. Elios Therapeutics
66. Emergent BioSolutions
67. Fisher Scientific (Acquired by Thermo Fisher Scientific)
68. FluGen
69. FUJIFILM Wako Pure Chemicals
70. GC Pharma
71. GeneOne Life Science
72. GlaxoSmithKline
73. Gradalis
74. HALIX
75. Heat Biologics
76. Hilleman Laboratories
77. Hookipa Biotech
78. Icahn School of Medicine at Mount Sinai
79. IDT Biologika
80. ILiAD Biotechnologies
81. Immunicum
82. ImmunoCellular Therapeutics
83. Immutep
84. Indian Immunologicals
85. Inovio Pharmaceuticals
86. Institut National de la Santé et de la Recherche Médicale (INSERM)
87. Insud Pharma
88. Intermountain Life Sciences
89. Intervet
90. InVitria
91. Invitrogen
92. Irvine Scientific Sales (Acquired by FUJIFILM)
93. IS JAPAN (Acquired by FUJIFILM)
94. Janssen Pharmaceuticals
95. Jianshun Biosciences
96. JN International Medical
97. JW CreaGene
98. Kansas State University
99. KBI Biopharma
100. Kiromic
101. Leland Stanford Junior University
102. LG Chem
103. LimmaTech Biologics
104. Lonza
105. Luina Bio
106. Massachusetts Institute of Technology
107. MassBiologics
108. Medicago
109. Medigen Vaccine Biologics
110. Medigene
111. Meissa Vaccines
112. Merck
113. Meridian Life Science
114. MilliporeSigma
115. MinervaX
116. Moderna
117. MolecuVax
118. Northwest Biotherapeutics
119. Nova Immunotherapeutics
120. Novartis
121. Novasep
122. Novavax
123. NPO Petrovax Pharm
124. Ology Bioservices
125. Oncobiomed
126. OPM Biosciences
127. Osivax
128. Oxford Biomedica
129. Pall Corporation
130. Panacea Biotec
131. Patheon Viral Vector Services
132. PDC*line Pharma
133. Pfizer
134. Premas Biotech
135. Prestige BioPharma
136. ProBioGen
137. Regeneus
138. Research Institute at Nationwide Children's Hospital
139. Sanaria
140. Sanofi Pasteur
141. Saronic Biotechnology
142. Sartorius
143. Scandinavian Biopharma
144. Seqirus
145. Serum Institute of India
146. Shanghai Bovax Biotechnology
147. Shenzhen Hornetcorn Biotechnology
148. Shenzhen Kangtai Biological Products
149. Sigma-Aldrich
150. SK Bioscience
151. SOTIO
152. Symbiosis Pharmaceutical Services
153. Takeda
154. TapImmune
155. Tella
156. Tessa Therapeutics
157. TeutoCell
158. Themis Bioscience
159. Thermo Electron
160. Thermo Fisher Scientific
161. Thousand Oaks Biopharmaceuticals
162. TNCbio
163. Unity Lab Services
164. University of California
165. University of Pennsylvania
166. University of Texas
167. USHEALTH
168. Vaccinogen
169. Vaccitech
170. Valneva
171. Vaxart
172. Vaxine
173. Vibalogics
174. Waisman Biomanufacturing
175. WuXi Biologics
176. Xell
177. XEME Biopharma
Please note that the publisher limits purchases by consulting clients to either Consulting Company Team License or Global Site License for Entire Company. Any other selections will not be fulfilled by this publisher.
Table of Contents
180 Pages
- 1. PREFACE
- 1.1. Scope of the Report
- 1.2. Research Methodology
- 1.3. Key Questions Answered
- 1.4. Chapter Outlines
- 2. EXECUTIVE SUMMARY
- 2.1. Chapter Overview
- 3. INTRODUCTION
- 3.1. Chapter Overview
- 3.2. Introduction to Viral Vaccine
- 3.2.1. Vaccine Components
- 3.2.2. Historical Evolution
- 3.2.3. Viral Vaccine Development
- 3.3. Type of Viral Vaccine
- 3.3.1. Whole Virus
- 3.3.2. Protein Subunit
- 3.3.3. Nucleic Acid
- 3.3.4 Viral Vector
- 3.4. Type of Cell Culture
- 3.5. Type of Cell Culture Media
- 3.6. Advantages of Cell Culture Media
- 3.7. Limitations Associated with Cell Culture Media
- 3.8. Conclusion
- 4. MARKET LANDSCAPE
- 4.1. Chapter Overview
- 4.2. Viral Vaccine Cell Culture Media: Overall Market Landscape
- 4.2.1. Analysis by Type of Vaccine
- 4.2.2. Analysis by Type of Cell Culture
- 4.2.3. Analysis by Type of Cell Culture Media
- 4.2.4. Analysis by Type of Cell Culture and Media
- 4.2.5. Analysis by Type of Cell Line
- 4.2.6. Analysis by Type of Cell Culture Media and Type of Cell Line
- 4.2.7. Analysis by Media Formulation
- 4.2.8. Analysis by Application Area
- 4.3. Viral Vaccine Cell Culture Media Developers: Market Landscape
- 4.3.1. Analysis by Year of Establishment
- 4.3.2. Analysis by Company Size
- 4.3.3. Analysis by Location of Headquarters
- 4.3.4. Analysis by Number of Products
- 5. COMPANY PROFILES
- 5.1. Chapter Overview
- 5.2. Players based in North America
- 5.2.1. Creative Biolabs
- 5.2.1.1. Company Overview
- 5.2.1.2. Financial Information
- 5.2.1.3. Product Portfolio
- 5.2.1.4. Future Outlook
- 5.2.2. Jianshun Biosciences
- 5.2.2.1. Company Overview
- 5.2.2.2. Financial Information
- 5.2.2.3. Product Portfolio
- 5.2.2.4. Future Outlook
- 5.2.3. Thermo Fisher Scientific
- 5.2.3.1. Company Overview
- 5.2.3.2. Financial Information
- 5.2.3.3. Product Portfolio
- 5.2.3.4. Future Outlook
- 5.3. Players based in Europe
- 5.3.1. Merck
- 5.3.1.1. Company Overview
- 5.3.1.2. Financial Information
- 5.3.1.3. Product Portfolio
- 5.3.1.4. Future Outlook
- 5.3.2. Sartorius
- 5.3.2.1. Company Overview
- 5.3.2.2. Financial Information
- 5.3.2.3. Product Portfolio
- 5.3.2.4. Future Outlook
- 5.3.3. Xell
- 5.3.3.1. Company Overview
- 5.3.3.2. Financial Information
- 5.3.3.3. Product Portfolio
- 5.3.3.4. Future Outlook
- 5.4. Players based in Asia-Pacific
- 5.4.1. ATZ labs
- 5.4.1.1. Company Overview
- 5.4.1.2. Financial Information
- 5.4.1.3. Product Portfolio
- 5.4.1.4. Future Outlook
- 5.4.2. OPM Biosciences
- 5.4.2.1. Company Overview
- 5.4.2.2. Financial Information
- 5.4.2.3. Product Portfolio
- 5.4.2.4. Future Outlook
- 6. RECENT DEVELOPMENTS AND INITIATIVES
- 6.1. Chapter Overview
- 6.2. Partnership Models
- 6.3. Viral Vaccine Cell Culture Media: Recent Partnerships and Collaborations
- 6.3.1. Analysis by Year of Partnership
- 6.3.2. Analysis by Type of Partnership
- 6.3.2.1. Analysis by Year and Type of Partnership
- 6.3.2.2. Analysis by Type of Partnership and Company Size
- 6.3.3. Most Active Players: Analysis by Number of Partnerships
- 6.3.4. Regional Analysis
- 6.3.4.1. Intercontinental and Intracontinental Agreements
- 6.3.5. Cumulative Year-wise Trend of Merger / Acquisition
- 6.3.6. Analysis by Type of Acquisition
- 6.3.7. Analysis by Key Value Drivers
- 6.3.8. Analysis by Year of Acquisition and Key Value Drivers
- 6.4. Viral Vaccine Cell Culture Media: Recent Expansions
- 7. LIKELY PARTNER ANALYSIS
- 7.1. Chapter Overview
- 7.2. Scope and Methodology
- 7.3. Potential Strategic Partners for Viral Vaccine Cell Culture Media Developers
- 7.3.1. Likely Partner Opportunities in Preventive Vaccine Developers
- 7.3.2. Likely Partner Opportunities in Therapeutic Vaccine Developers
- 7.3.3. Likely Partner Opportunities in Vaccine Contract Manufacturers
- 8. PRODUCT COMPETITIVENESS ANALYSIS
- 8.1. Chapter Overview
- 8.2. Methodology
- 8.3. Assumptions / Key Parameters
- 8.4. Product Competitiveness: Adherent Cell Culture Media
- 8.5. Product Competitiveness: Suspension Cell Culture Media
- 9. BRAND POSITIONING
- 9.1. Chapter Overview
- 9.2. Key Parameters and Methodology
- 9.3. Brand Positioning Matrix: Cytiva
- 9.4. Brand Positioning Matrix: FUJIFILM Wako Chemicals
- 9.5. Brand Positioning Matrix: Lonza
- 9.6. Brand Positioning Matrix: Merck
- 9.7. Brand Positioning Matrix: Sartorius
- 9.8. Brand Positioning Matrix: Thermo Fisher Scientific
- 10. PATENT ANALYSIS
- 10.1. Chapter Overview
- 10.2. Scope and Methodology
- 10.3. Viral Vaccine Cell Culture Media: Patent Analysis
- 10.3.1. Analysis by Type of Patent
- 10.3.2. Analysis by Publication Year
- 10.3.3. Analysis by Granted Patents
- 10.3.4. Year-wise Trend of Filed Patent Applications
- 10.3.5. Analysis by Issuing Authority
- 10.3.6. Analysis by Patent Focus
- 10.3.7. Analysis by Patent Age
- 10.3.8. Analysis by CPC Symbols
- 10.3.9. Analysis by Type of Applicant
- 10.3.10. Leading Players: Analysis by Number of Patents
- 10.4. Viral Vaccine Cell Culture Media: Patent Benchmarking Analysis
- 10.4.1. Analysis by Patent Characteristics
- 10.4.2. Analysis by Geography
- 10.5. Viral Vaccine Cell Culture Media: Patent Valuation Analysis
- 11. DEMAND ANALYSIS
- 11.1. Chapter Overview
- 11.2. Scope and Methodology
- 11.3. Global Demand for Viral Vaccine
- 11.3.1. Global Demand for Scale of Operation
- 11.3.1.1. Clinical Demand for Viral Vaccine
- 11.3.1.2. Commercial Demand for Viral Vaccine
- 11.4.1. Geographical Analysis of Demand
- 11.4.1.1. Overall Demand in North America for Viral Vaccine
- 11.4.1.2. Overall Demand in Europe for Viral Vaccine
- 11.4.1.3. Overall Demand in Asia-Pacific and Rest of the World for Viral Vaccine
- 12. MARKET FORECAST
- 12.1. Chapter Overview
- 12.2. Forecast Methodology and Key Assumptions
- 12.3. Global Viral Vaccine Cell Culture Media Market, 2022-2035
- 12.4. Viral Vaccine Cell Culture Media Market: Analysis by Type of Cell Culture, 2022-2035
- 12.4.1. Viral Vaccine Cell Culture Media Market for Adherent Cell Culture, 2022-2035
- 12.4.2. Viral Vaccine Cell Culture Media Market for Suspension Cell Culture, 2022-2035
- 12.5. Viral Vaccine Cell Culture Media Market: Analysis by Type of Cell Culture Media, 2022-2035
- 12.5.1. Viral Vaccine Cell Culture Media Market for Animal Component Free Media, 2022-2035
- 12.5.2. Viral Vaccine Cell Culture Media Market for Protein Free Media, 2022-2035
- 12.5.3. Viral Vaccine Cell Culture Media Market for Serum Free Media, 2022-2035
- 12.6. Viral Vaccine Cell Culture Media Market: Analysis by Scale of Operation, 2022-2035
- 12.6.1. Viral Vaccine Cell Culture Media Market for Clinical Operations, 2022-2035
- 12.6.2. Viral Vaccine Cell Culture Media Market for Commercial Operations, 2022-2035
- 12.7. Viral Vaccine Cell Culture Media Market: Analysis by Type of End-User, 2022-2035
- 12.7.1. Viral Vaccine Cell Culture Media Market for Industry Players, 2022-2035
- 12.7.2. Viral Vaccine Cell Culture Media Market for Non-Industry Players, 2022-2035
- 12.8. Viral Vaccine Cell Culture Media Market: Analysis by Geography, 2022-2035
- 12.8.1. Viral Vaccine Cell Culture Media Market in North America, 2022-2035
- 12.8.2. Viral Vaccine Cell Culture Media Market in Europe, 2022-2035
- 12.8.3. Viral Vaccine Cell Culture Media Market in Asia-Pacific, 2022-2035
- 12.8.4. Viral Vaccine Cell Culture Media Market in Rest of the World, 2022-2035
- 13. CONCLUSION
- 13.1. Chapter Overview
- 14. INTERVIEW TRANSCRIPT(S)
- 15. APPENDIX I: TABULATED DATA
- 16. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
- LIST OF FIGURES
- Figure 2.1 Executive Summary: Overall Market Landscape
- Figure 2.2 Executive Summary: Recent Developments and Initiatives
- Figure 2.3 Executive Summary: Patent Analysis
- Figure 2.4 Executive Summary: Demand Analysis
- Figure 2.5 Executive Summary: Market Forecast
- Figure 3.1 Components of Vaccine
- Figure 3.2 Stages of Viral Vaccine Development
- Figure 3.3 Types of Viral Vaccines
- Figure 3.4 Types of Cell Culture Media
- Figure 4.1 Viral Vaccine Cell Culture Media: Distribution by Types of Vaccines
- Figure 4.2 Viral Vaccine Cell Culture Media: Distribution by Types of Cell Culture
- Figure 4.3 Viral Vaccine Cell Culture Media: Distribution by Types of Cell Culture Media
- Figure 4.4 Viral Vaccine Cell Culture Media: Distribution by Types of Cell Culture and Media
- Figure 4.5 Viral Vaccine Cell Culture Media: Distribution by Type of Cell Line
- Figure 4.6 Viral Vaccine Cell Culture Media: Distribution by Types of Cell Culture Media and Type of Cell Line
- Figure 4.7 Viral Vaccine Cell Culture Media: Distribution by Application Area
- Figure 4.8 Viral Vaccine Cell Culture Media Developers: Distribution by Year of Establishment
- Figure 4.9 Viral Vaccine Cell Culture Media Developers: Distribution by Company Size
- Figure 4.10 Viral Vaccine Cell Culture Media Developers: Distribution by Location of Headquarters
- Figure 4.11 Most Active Players: Distribution by Number of Products
- Figure 5.1 Thermo Fisher Scientific: Annual Revenues, 2016 – 9M 2021 (USD Billion)
- Figure 5.2 Merck: Annual Revenues, 2016 – 9M 2021 (EUR Billion)
- Figure 5.3 Sartorius: Annual Revenues, 2016 – 9M 2021 (EUR Million)
- Figure 6.1 Partnerships and Collaborations: Distribution by Year of Partnership
- Figure 6.2 Partnerships and Collaborations: Distribution by Types of Partnership
- Figure 6.3 Partnerships and Collaborations: Distribution by Year and Types of Partnership
- Figure 6.4 Partnerships and Collaborations: Distribution by Types of Partnership and Company Size
- Figure 6.5 Most Active Players: Distribution by Number of Partnerships
- Figure 6.6 Partnerships and Collaborations: Regional Distribution
- Figure 6.7 Partnerships and Collaborations: Country-wise Distribution
- Figure 6.8 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
- Figure 9.1 Brand Positioning Analysis: Competitive Advantage of Key Industrial Players
- Figure 9.2 Brand Positioning Analysis: Reasons to Believe
- Figure 9.3 Brand Positioning Matrix: Cytiva
- Figure 9.4 Brand Positioning Matrix: FUJIFILM Wako Chemicals
- Figure 9.5 Brand Positioning Matrix: Lonza
- Figure 9.6 Brand Positioning Matrix: Merck
- Figure 9.7 Brand Positioning Matrix: Sartorius
- Figure 9.8 Brand Positioning Matrix: Thermo Fisher Scientific
- Figure 10.1 Patent Analysis: Distribution by Type of Patent
- Figure 10.2 Patent Analysis: Cumulative Distribution by Publication Year, 2015-2021
- Figure 10.3 Patent Analysis: Distribution of Granted Patents by Publication Year, 2015-2021
- Figure 10.4 Patent Analysis: Distribution of Filed Patents by Publication Year, 2015-2021
- Figure 10.5 Patent Analysis: Distribution by Issuing Authority
- Figure 10.6 Patent Analysis: Distribution by Patent Focus
- Figure 10.7 Patent Analysis: Distribution by Patent Age
- Figure 10.8 Patent Analysis: Distribution by CPC Symbols
- Figure 10.9 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant (2015 - 2021)
- Figure 10.10 Leading Players Assignees: Distribution by Number of Patents
- Figure 10.11 Patent Analysis (Top 10 CPC Symbols): Benchmarking by Leading Players
- Figure 10.12 Patent Analysis: Benchmarking by International Patents
- Figure 10.13 Patent Valuation Analysis
- Figure 11.1 Clinical Demand for Viral Vaccine, 2022-2035 (Million Liters)
- Figure 11.2 Commercial Demand for Viral Vaccine, 2022-2035 (Million Liters)
- Figure 11.3 Global Demand for Viral Vaccine in North America, 2022-2035 (Million Liters)
- Figure 11.4 Global Demand for Viral Vaccine in Europe, 2022-2035 (Million Liters)
- Figure 11.5 Global Demand for Viral Vaccine in Asia-Pacific and Rest of the World, 2022-2035 (Million Liters)
- Figure 12.1 Global Viral Vaccine Cell Culture Media Market, 2022-2035 (USD Billion)
- Figure 12.2 Viral Vaccine Cell Culture Media Market: Distribution by Types of Cell Culture, 2022 and 2032
- Figure 12.3 Viral Vaccine Cell Culture Media Market for Adherent Cell Culture, 2022-2035 (USD Million)
- Figure 12.4 Viral Vaccine Cell Culture Media Market for Suspension Cell Culture, 2022-2035 (USD Million)
- Figure 12.5 Viral Vaccine Cell Culture Media Market: Distribution by Types of Cell Culture Media, 2022 and 2032
- Figure 12.6 Viral Vaccine Cell Culture Media Market for Animal Component Free Media, 2022-2035 (USD Million)
- Figure 12.7 Viral Vaccine Cell Culture Media Market for Protein Free Media, 2022-2035 (USD Million)
- Figure 12.8 Viral Vaccine Cell Culture Media Market for Serum Free Media, 2022-2035 (USD Million)
- Figure 12.9 Viral Vaccine Cell Culture Media Market: Distribution by Scale of Operation, 2022 and 2032
- Figure 12.10 Viral Vaccine Cell Culture Media Market for Clinical Operations, 2022-2035 (USD Million)
- Figure 12.11 Viral Vaccine Cell Culture Media Market for Commercial Operations, 2022-2035 (USD Million)
- Figure 12.12 Viral Vaccine Cell Culture Media Market: Distribution by Types of End-User, 2022 and 2032
- Figure 12.13 Viral Vaccine Cell Culture Media Market for Industry Players, 2022-2035 (USD Million)
- Figure 12.14 Viral Vaccine Cell Culture Media Market for Non-Industry Players, 2022-2035 (USD Million)
- Figure 12.15 Viral Vaccine Cell Culture Media Market: Distribution by Geography, 2022 and 2032
- Figure 12.16 Viral Vaccine Cell Culture Media Market in North America, 2022-2035 (USD Million)
- Figure 12.17 Viral Vaccine Cell Culture Media Market in Europe, 2022-2035 (USD Million)
- Figure 12.18 Viral Vaccine Cell Culture Media Market in Asia-Pacific, 2022-2035 (USD Million)
- Figure 12.19 Viral Vaccine Cell Culture Media Market in Rest of the World, 2022-2035 (USD Million)
- Figure 13.1 Concluding Remarks: Current Market Landscape
- Figure 13.2 Concluding Remarks: Recent Developments and Initiatives
- Figure 13.3 Concluding Remarks: Patent Analysis
- Figure 13.4 Concluding Remarks: Demand Analysis
- Figure 13.5 Concluding Remarks: Market Sizing and Opportunity Analysis
- LIST OF TABLES
- Table 3.1 Comparison between Adherent and Suspension Cell Culture
- Table 4.1 Viral Vaccine Cell Culture Media: Information on Developer, Types of Vaccine, and Virus Cultured
- Table 4.2 Viral Vaccine Cell Culture Media: Information on Types of Cell Culture and Types of Cell Culture Media
- Table 4.3 Viral Vaccine Cell Culture Media: Information on Type of Cell Line
- Table 4.4 Viral Vaccine Cell Culture Media: Information on Media Formulation, Available Package Volume and Price
- Table 4.5 Viral Vaccine Cell Culture Media: Information on Application Area, Accreditations Received, Types of End-User and Scale of Operation
- Table 4.6 Viral Vaccine Cell Culture Media Developers: Information on Year of Establishment, Company Size and Location of Headquarters
- Table 5.1 Creative Biolabs: Company Snapshot
- Table 5.2 Creative Biolabs: Product Portfolio
- Table 5.3 Jianshun Biosciences: Company Snapshot
- Table 5.4 Jianshun Biosciences: Product Portfolio
- Table 5.5 Thermo Fisher Scientific: Company Snapshot
- Table 5.6 Thermo Fisher Scientific: Product Portfolio
- Table 5.7 Merck: Company Snapshot
- Table 5.8 Merck: Product Portfolio
- Table 5.9 Merck: Recent Developments and Future Outlook
- Table 5.10 Sartorius: Company Snapshot
- Table 5.11 Sartorius: Product Portfolio
- Table 5.12 Sartorius: Recent Developments and Future Outlook
- Table 5.13 Xell: Company Snapshot
- Table 5.14 Xell: Product Portfolio
- Table 5.15 Xell: Recent Developments and Future Outlook
- Table 5.16 ATZ labs: Company Snapshot
- Table 5.17 ATZ labs: Product Portfolio
- Table 5.18 OPM Biosciences: Company Snapshot
- Table 5.19 OPM Biosciences: Product Portfolio
- Table 6.1 Partnerships and Collaborations: List of Partnership, 2015-2021
- Table 6.2 Viral Vaccine Cell Culture Media: List of Recent Expansions, 2015-2021
- Table 7.1 Likely Partners for Preventive Vaccine Developers
- Table 7.2 Likely Partners for Therapeutic Vaccine Developers
- Table 7.3 Likely Partners for Vaccine Contract Manufacturers
- Table 8.1 Product Competitiveness Analysis: Adherent Cell Culture Media
- Table 8.2 Product Competitiveness Analysis: Suspension Cell Culture Media
- Table 10.1 Patent Analysis: Distribution by CPC Symbols
- Table 10.2 Patent Analysis: Most Popular CPC Symbols
- Table 10.3 Patent Analysis: List of Top CPC Symbols
- Table 10.4 Patent Analysis: Categorization based on Weighted Valuation Scores
- Table 10.5 Leading Patents: Distribution by Number of Citations
- Table 13.1 Conclusion: Overall Market Landscape
- Table 13.2 Conclusion: Recent Developments and Initiatives
- Table 13.3 Conclusion: Patent Analysis
- Table 13.4 Conclusion: Demand Analysis
- Table 13.5 Conclusion: Market Forecast
- Table 15.1 Viral Vaccine Cell Culture Media: Distribution by Types of Vaccines
- Table 15.2 Viral Vaccine Cell Culture Media: Distribution by Types of Cell Culture
- Table 15.3 Viral Vaccine Cell Culture Media: Distribution by Types of Cell Culture Media
- Table 15.4 Viral Vaccine Cell Culture Media: Distribution by Types of Cell Culture and Media
- Table 15.5 Viral Vaccine Cell Culture Media: Distribution by Type of Cell Line
- Table 15.6 Viral Vaccine Cell Culture Media: Distribution by Types of Cell Culture Media and Type of Cell Line
- Table 15.7 Viral Vaccine Cell Culture Media: Distribution by Media Formulation
- Table 15.8 Viral Vaccine Cell Culture Media: Distribution by Application Area
- Table 15.9 Viral Vaccine Cell Culture Media Developers: Distribution by Year of Establishment
- Table 15.10 Viral Vaccine Cell Culture Media Developers: Distribution by Company Size
- Table 15.11 Viral Vaccine Cell Culture Media Developers: Distribution by Location of Headquarters
- Table 15.12 Most Active Players: Distribution by Number of Products
- Table 15.13 Thermo Fisher Scientific: Annual Revenues, 2016 –9M 2021 (USD Billion)
- Table 15.14 Merck: Annual Revenues, 2016 –9M 2021 (EUR Billion)
- Table 15.15 Sartorius: Annual Revenues, 2016 – 9M 2021 (EUR Million)
- Table 15.16 Partnerships and Collaborations: Distribution by Year of Partnership
- Table 15.17 Partnerships and Collaborations: Distribution by Types of Partnership
- Table 15.18 Partnerships and Collaborations: Distribution by Year and Types of Partnership
- Table 15.19 Partnerships and Collaborations: Distribution by Types of Partnership and Company Size
- Table 15.20 Most Active Players: Distribution by Number of Partnerships
- Table 15.21 Partnerships and Collaborations: Regional Distribution
- Table 15.22 Partnerships and Collaborations: Country-wise Distribution
- Table 15.23 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
- Table 15.24 Patent Analysis: Distribution by Type of Patent
- Table 15.25 Patent Analysis: Cumulative Distribution by Publication Year, 2015 – 2021
- Table 15.26 Patent Analysis: Distribution of Granted Patents by Publication Year, 2015-2021
- Table 15.27 Patent Analysis: Distribution of Filed Patents by Publication Year, 2015 - 2021
- Table 15.28 Patent Analysis: Distribution by Issuing Authority
- Table 15.29 Patent Analysis: Distribution by Patent Age
- Table 15.30 Patent Analysis: Distribution by CPC Symbols
- Table 15.31 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant (2015 - 2021)
- Table 15.32 Leading Players Assignees: Distribution by Number of Patents
- Table 15.33 Patent Analysis (Top 10 CPC Symbols): Benchmarking by Leading Players
- Table 15.34 Patent Analysis: Benchmarking by International Patents
- Table 15.35 Patent Valuation Analysis
- Table 15.36 Clinical Demand for Viral Vaccine, 2022-2035 (Million Liters)
- Table 15.37 Commercial Demand for Viral Vaccine, 2022-2035 (Million Liters)
- Table 15.38 Global Demand for Viral Vaccine in North America, 2022-2035 (Million Liters)
- Table 15.39 Global Demand for Viral Vaccine in Europe, 2022-2035 (Million Liters)
- Table 15.40 Global Demand for Viral Vaccine in Asia-Pacific and Rest of the World, 2022-2035 (Million Liters)
- Table 15.41 Global Viral Vaccine Cell Culture Media Market, 2022-2035 (USD Billion)
- Table 15.42 Viral Vaccine Cell Culture Media Market: Distribution by Types of Cell Culture, 2022 and 2032
- Table 15.43 Viral Vaccine Cell Culture Media Market for Adherent Cell Culture, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
- Table 15.44 Viral Vaccine Cell Culture Media Market for Suspension Cell Culture, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
- Table 15.45 Viral Vaccine Cell Culture Media Market: Distribution by Types of Cell Culture Media, 2022 and 2032
- Table 15.46 Viral Vaccine Cell Culture Media Market for Animal Component Free Media, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
- Table 15.47 Viral Vaccine Cell Culture Media Market for Protein Free Media, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
- Table 15.48 Viral Vaccine Cell Culture Media Market for Serum Free Media, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
- Table 15.49 Viral Vaccine Cell Culture Media Market: Distribution by Scale of Operation, 2022 and 2032
- Table 15.50 Viral Vaccine Cell Culture Media Market for Clinical Operations, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
- Table 15.51 Viral Vaccine Cell Culture Media Market for Commercial Operations, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
- Table 15.52 Viral Vaccine Cell Culture Media Market: Distribution by Types of End-User, 2022 and 2032
- Table 15.53 Viral Vaccine Cell Culture Media Market for Industry Players, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
- Table 15.54 Viral Vaccine Cell Culture Media Market for Non-Industry Players, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
- Table 15.55 Viral Vaccine Cell Culture Media Market: Distribution by Geography, 2022 and 2032
- Table 15.56 Viral Vaccine Cell Culture Media Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
- Table 15.57 Viral Vaccine Cell Culture Media Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
- Table 15.58 Viral Vaccine Cell Culture Media Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
- Table 15.59 Viral Vaccine Cell Culture Media Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
